179 related articles for article (PubMed ID: 28462832)
1. 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases.
Thompson AM; Blaser A; Palmer BD; Anderson RF; Shinde SS; Launay D; Chatelain E; Maes L; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
Bioorg Med Chem Lett; 2017 Jun; 27(11):2583-2589. PubMed ID: 28462832
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
Palmer BD; Sutherland HS; Blaser A; Kmentova I; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA; Thompson AM
J Med Chem; 2015 Apr; 58(7):3036-59. PubMed ID: 25781074
[TBL] [Abstract][Full Text] [Related]
3. Recent Progress in the Discovery and Development of 2-Nitroimidazooxazines and 6-Nitroimidazooxazoles to Treat Tuberculosis and Neglected Tropical Diseases.
Showalter HD
Molecules; 2020 Sep; 25(18):. PubMed ID: 32927749
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.
Sasaki H; Haraguchi Y; Itotani M; Kuroda H; Hashizume H; Tomishige T; Kawasaki M; Matsumoto M; Komatsu M; Tsubouchi H
J Med Chem; 2006 Dec; 49(26):7854-60. PubMed ID: 17181168
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis.
Upton AM; Cho S; Yang TJ; Kim Y; Wang Y; Lu Y; Wang B; Xu J; Mdluli K; Ma Z; Franzblau SG
Antimicrob Agents Chemother; 2015 Jan; 59(1):136-44. PubMed ID: 25331696
[TBL] [Abstract][Full Text] [Related]
6. Biarylmethoxy 2-nitroimidazooxazine antituberculosis agents: Effects of proximal ring substitution and linker reversal on metabolism and efficacy.
Thompson AM; Blaser A; Palmer BD; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
Bioorg Med Chem Lett; 2015 Sep; 25(18):3804-9. PubMed ID: 26253632
[TBL] [Abstract][Full Text] [Related]
7. Delamanid: first global approval.
Ryan NJ; Lo JH
Drugs; 2014 Jun; 74(9):1041-5. PubMed ID: 24923253
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis.
Ashtekar DR; Costa-Perira R; Nagrajan K; Vishvanathan N; Bhatt AD; Rittel W
Antimicrob Agents Chemother; 1993 Feb; 37(2):183-6. PubMed ID: 8452346
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of anti-tubercular and antibacterial activities of new 4-(2,6-dichlorobenzyloxy)phenyl thiazole, oxazole and imidazole derivatives. Part 2.
Lu X; Liu X; Wan B; Franzblau SG; Chen L; Zhou C; You Q
Eur J Med Chem; 2012 Mar; 49():164-71. PubMed ID: 22264895
[TBL] [Abstract][Full Text] [Related]
10. Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.
Moraski GC; Markley LD; Chang M; Cho S; Franzblau SG; Hwang CH; Boshoff H; Miller MJ
Bioorg Med Chem; 2012 Apr; 20(7):2214-20. PubMed ID: 22391032
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.
Rakesh ; Bruhn DF; Scherman MS; Singh AP; Yang L; Liu J; Lenaerts AJ; Lee RE
Bioorg Med Chem Lett; 2016 Jan; 26(2):388-391. PubMed ID: 26711150
[TBL] [Abstract][Full Text] [Related]
12. Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.
Thompson AM; O'Connor PD; Blaser A; Yardley V; Maes L; Gupta S; Launay D; Martin D; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
J Med Chem; 2016 Mar; 59(6):2530-50. PubMed ID: 26901446
[TBL] [Abstract][Full Text] [Related]
13. Novel 2-(2-benzylidenehydrazinyl)benzo[d]thiazole as potential antitubercular agents.
Bairwa VK; Telvekar VN
Comb Chem High Throughput Screen; 2013 Mar; 16(3):244-7. PubMed ID: 23176058
[TBL] [Abstract][Full Text] [Related]
14. OPC-67683.
Tuberculosis (Edinb); 2008 Mar; 88(2):132-3. PubMed ID: 18486051
[No Abstract] [Full Text] [Related]
15. Delamanid Kills Dormant Mycobacteria
Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
[TBL] [Abstract][Full Text] [Related]
16. 7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.
Thompson AM; O'Connor PD; Marshall AJ; Yardley V; Maes L; Gupta S; Launay D; Braillard S; Chatelain E; Franzblau SG; Wan B; Wang Y; Ma Z; Cooper CB; Denny WA
J Med Chem; 2017 May; 60(10):4212-4233. PubMed ID: 28459575
[TBL] [Abstract][Full Text] [Related]
17. Discovery and evaluation of novel nitrodihydroimidazooxazoles as promising anti-tuberculosis agents.
Tao X; Gao C; Huang ZG; Luo W; Liu KL; Peng CT; Ding CZ; Li J; Chen SH; Yu LT
Bioorg Med Chem Lett; 2019 Sep; 29(17):2511-2515. PubMed ID: 31353295
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, structure and biological evaluation of novel bicyclic nitroimidazole derivatives.
Zaprutko L; Zwawiak J; Augustynowicz-Kopeć E; Zwolska Z; Bartoszak-Adamska E; Nowicki W
Arch Pharm (Weinheim); 2012 Jun; 345(6):463-7. PubMed ID: 22266946
[TBL] [Abstract][Full Text] [Related]
19. Delamanid or pretomanid? A Solomonic judgement!
Mudde SE; Upton AM; Lenaerts A; Bax HI; De Steenwinkel JEM
J Antimicrob Chemother; 2022 Mar; 77(4):880-902. PubMed ID: 35089314
[TBL] [Abstract][Full Text] [Related]
20. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
Kwon YS; Jeong BH; Koh WJ
Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
